Category: RJ Hamster

RJ Hamster

thetradersintelligence.com

RJ Hamster

🌟 Homebuilder Earnings: D.R. Horton Sticks Out as Pulte…

Unsubscribe

Ticker Reports for April 27^th

CRDO $179.17 (-8.14%)

CMPS $9.02 (-5.90%)

DHI $159.93 (+0.02%)

→ Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
(From Banyan Hill Publishing)

AI Insider Selling: Sales Hit Photronics, Credo & CoreWeave as Shares Spike

Insiders are making moves in three soaring artificial intelligence (AI) stocks, selling millions’ worth of shares. However, knowing which of these sales clearly signal negative indicators to investors and which do not requires a thorough analysis. Here’s what recent insider trades are signaling.

Phontronic’s Insider Sales Soar Alongside Shares

First up is a name that garnered significant attention near the end of 2025, Photronics (NASDAQ: PLAB). Photronics sells photomasks, key components in the semiconductor manufacturing process. The stock saw an over 45% single-day spike in December. This was the result of an impressive earnings report and the announcement of significant capital expenditures, indicating strong demand going forward. Photronics has continued to soar in 2026, already up more than 50% for the year.

However, as shares move up, Photronics has also seen a fair bit of insider selling in Q2. Overall, MarketBeat has tracked $14 million worth of selling during the quarter, a big-time shift from just $3.44 million in Q1.

Notably, none of these sales came under a predetermined 10b5-1 plan, indicating that they were discretionary in nature. Furthermore, many of these sales represented a significant portion of individual insider holdings. For example, insiders Hsueh-Chun Wang and Rui Zhang each reduced their holdings by 20% or more.

Given the significant appreciation seen in Photronics shares, these sales are a moderately bearish sign for the stock. Still, most insiders continue to hold large stakes in the company, suggesting that they maintain a solid degree of confidence going forward.

Credo Insiders Sell as Shares as Hit New Highs

Next up is Credo Technology Group (NASDAQ: CRDO), an AI stock that has experienced significant ups and downs over the recent past. The stock rose to nearly $190 in early December 2025, before falling to less than $100 by early March 2026. Within two months, Credo saw a significant recovery, rising above $190. In late April, Credo moved to all-time highs near $195. Much of this enthusiasm comes as Credo agreed to acquire DustPhotonics, adding more optical networking products to its primarily copper-based lineup.

As Credo shares surge to unprecedented levels, insiders are capitalizing, selling around $21 million worth of shares in Q2. Still, less than a month into Q2, this selling is largely consistent with Q1 selling. Over those full three months, sales came in near $53 million.

Additionally, the majority of Q2 sales came under 105b-1 plans or were relatively small as a percentage of individual holdings, making them not overly concerning. For example, despite making multiple sales, Chi Fung Cheng lowered total shares held by less than 2% and still holds over 6 million Credo shares.

Given these mitigating circumstances, Credo’s Q2 sales do not provide much of a negative signal.

CoreWeave’s Insider Sales Rise by More Than 3X in Q2

Last up is one of the AI trade’s most well-known newcomers, neo-cloud company CoreWeave (NASDAQ: CRWV). CoreWeave has also been a highly volatile stock since going public in March 2025. The stock moved up to over $180 in June 2025, before ending the year near $70. CoreWeave has seen a huge recovery in 2026, up almost 50% to around $107 per share.

Throughout its publicly traded history, CoreWeave has seen a very large amount of insider selling, at $6.55 billion. After a big drop in selling during Q1, insiders are stepping up their sales again. In April alone, MarketBeat has tracked more than $1.3 billion in sales, over three times higher than the $396 million in sales that took place in all of Q1.

Importantly, many of CoreWeave’s sales came under 105b-1 plans or had other mitigating factors. However, this is not true of one of CoreWeave’s largest insiders, hedge fund Magnetar Financial. Magnetar has sold hundreds of millions of dollars’ worth of CoreWeave shares in Q2. Despite big-time sales, Magnetar continues to indirectly hold billions of dollars’ worth of CoreWeave. Clearly, insiders are selling more as CoreWeave rises, a negative signal.

CoreWeave: Insiders Sell, Analysts Disagree

Among this group, CoreWeave’s insider selling activity is the most noteworthy. Notwithstanding recent selling, the huge value of trades around CoreWeave is a significant technical overhang on the stock. Magnetar has shown a consistent pattern of selling its shares, and the company still has massive exposure to CoreWeave. Due to this, the overhang is unlikely to abate soon.

Still, Wall Street analysts continue to take a generally bullish view on the stock. The MarketBeat consensus price target near $125 implies more than 15% upside in shares. The range of targets on CoreWeave is very wide. Targets updated in April stretch as high as $175 and as low as $67. These figures imply upside of more than 60% and downside of more than 35%, respectively, illustrating the large degree of uncertainty around this name.

Ad Banyan Hill Publishing

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company👉 Unlock The Ticker Now And Get It Completely Free.

These 3 Psychedelic Stocks Activated After Trump’s Executive Order

The Trump administration’s April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors in the midst of the Iran war and numerous other high-profile domestic political news stories, but the implications for this small but growing industry are tremendous. Indeed, within days, the FDA began to make moves, awarding national priority vouchers to select companies developing drugs in this category, thereby reducing drug review times considerably.

Single-session wins were to be expected for some of the bigger players in the psychedelics industry, and sure enough, share prices for several of these companies skyrocketed. As time goes on, though, it will be up to these drug developers to prove that they have the medicines to back up the newfound hype. These are some companies that may be worth watching.

A Promising Candidate Could Make It to Market Sooner, Preempting Financial Challenges

One of the biggest beneficiaries of the executive order was biotech firm Compass Pathways (NASDAQ: CMPS), which has seen its share price surge by nearly 80% in the last month. Specifically, the enthusiasm centers on its COMP360, a drug candidate for treatment-resistant depression and a recipient of a priority voucher.

For Compass, one challenge has been maintaining operational viability while developing a drug that appears to be quite promising. The company has faced mounting net losses in recent years, and losses per share have widened even as the weighted average basic shares outstanding have more than doubled in the last several years.

A shorter runway to commercialization for COMP360 could significantly help Compass overcome these hurdles. While the firm was already flagged as a Buy by several analysts, it received a wave of new bullish ratings and price targets immediately following the executive order. It heads into late April with eight out of 10 ratings as a Buy and over 100% in upside potential, even after its recent rally.

Another Speculative Penny Stock With a Promising Candidate

Another clinical-stage biotech with a potential psychedelic-based treatment for certain types of depression, AtaiBeckley (NASDAQ: ATAI) also saw a stock surge in mid-April. Though Phase 3 trials of its BPL-003 won’t begin until later in 2026, AtaiBeckley reported positive results from an earlier phase in April.

For its current sales—just $4 million annually—AtaiBeckley has a sky-high price-to-sales (P/S) ratio in the 400s, which would typically indicate that ATAI’s shares are massively overvalued. And in addition to being a pre-profit biotech name, the firm is also a penny stock, with shares priced below $5 even after the latest boost. That’s all to say that AtaiBeckley is a speculative investment, likely subject to volatility.

Still, the momentum behind psychedelic treatments for mental health disorders may help the company to bring BPL-003 to market sooner than initially expected, potentially. Ten out of 12 analysts across Wall Street view the stock positively, and its consensus price target of $14.63 suggests more than 200% in upside, significantly higher than CMPS.

A Potential Generalized Anxiety Disorder Treatment and Strong Analyst Support

Definium Therapeutics Inc. (NASDAQ: DFTX), previously known as Mind Medicine, has also faced significant net losses in recent years, although the fact that it ended 2025 with $258 million in cash and equivalents does buy it some much-needed time to move ahead with its MM120, a drug candidate for generalized anxiety disorder. Like both of the drugs above, MM120 has a potential addressable market that is colossal, and successfully commercializing the treatment could turn Definium from a speculative play into a dominant player in the biopharma field.

DFTX shares have only risen by about a quarter in the last month amid the news about the executive order, but analysts are more optimistic about this stock than either of the others above. It has 14 Buy ratings and only a single Sell, with forecasts of about 70% upside potential.

If all of the companies above seem too much of a risk, even after the recent push to accelerate the approval timeline for psychedelic drugs, investors might want to build diversified exposure to the industry with a niche exchange-traded fund like the AdvisorShares Psychedelics ETF (NYSEARCA: PSIL). This fund is actively managed, which likely contributes to its high expense ratio of 1%, but it provides ready-made access to about two dozen companies in the space. This can position investors to benefit when any of those firms experiences a big breakthrough—and can insulate when trial results don’t turn out as hoped. PSIL also offers a compelling dividend yield around 8.5% to further sweeten the deal.

Ad InvestorPlace

“Golden Dawn”: the code name that should be on every investor’s radar

“Golden Dawn”: the code name that should be on every investor’s radarWatch Louis Navellier’s Free Golden Dawn Presentation And Get The Ticker

Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales Tank

Homebuilders have been going through a rough patch as of late. Across top homebuilding stocks, analysts expected revenues and earnings to fall considerably in Q1 2026, and this is exactly what happened.

For over a year, stocks in this industry have been range-bound. The SPDR S&P Homebuilders ETF (NYSEARCA: XHB) is a commonly used proxy for this industry, tracking the performance of over 30 homebuilders or housing-related stocks. The fund has delivered an approximate total return of just 5% since the start of 2025. With interest rates still relatively high and housing affordability low, stocks in this space have struggled to gain much momentum.

Three of the top U.S. homebuilders just reported earnings; here’s how they stacked up and what it signals about the industry going forward.

Pulte’s EPS Falls 30%, Analysts Point to Moderate Upside

Pulte Group (NYSE: PHM) is one of the more diversified U.S. homebuilders targeting a balanced mix of market segments. In Q1, 38% of the company’s sales came from first-time buyers, while “move-up” buyers accounted for 39%. Its “active adult” buyer group, which includes sales in 55+ communities, accounted for 23% of sales.

Pulte saw its sales fall by 12% year over year (YOY) to $3.41 billion, essentially in line with estimates.

The significant decline came even as the company offered much greater incentives to home buyers. This led to a substantial 310 basis point compression in gross home sales margin.

In turn, adjusted earnings per share (EPS) tanked by just over 30% to $1.79, 1 cent short of estimates. The company’s new orders grew moderately by 3% YOY, similar to the 4% increase seen in Q4 2025, but Pulte did not change its guidance for the full year.

Still, Pulte saw a modest 2.4% gain after its report, indicating that the results were better than some investors had feared.

Several analysts tracked by MarketBeat raised their price targets after the report, with updates averaging around $147. This figure implies healthy upside in shares and is slightly above the MarketBeat consensus price target of around $141.

D.R. Horton Outperforms Against Low Expectations, Targets Spread

Homebuilding behemoth D.R. Horton (NYSE: DHI)was a clear standout. The company, which focuses on first-time home buyers, posted revenue of $7.56 billion. This marked a moderate 2% YOY drop, roughly in line with expectations and by far the best figure among this group. The firm also posted a solid bottom-line beat, with adjusted EPS of $2.24 versus estimates of $2.15. The figure fell by 13% YOY.

Forward-looking metrics were particularly strong, with home orders rising by 11% YOY, the highest rate among these names. The company did slightly lower the top end of its full-year guidance to $34.5 billion, but its midpoint estimate of $34 billion still exceeded estimates.

D.R. Horton also saw considerable margin compression, with the firm’s adjusted home sales gross margin declining by 230 basis points to 19.7%. Overall, these results allowed DHI shares to soar by nearly 6% post-earnings.

The MarketBeat consensus price target near $169 implies only around 5% upside in shares. Notably, all analysts who issued updates after the report raised their price targets; however, updated targets averaged around $165. They also showed significant variance, ranging from $206 to $123. These figures imply upside of more than 25% and downside of more than 20%, respectively.

NVR: Sales Plummet, Order Growth Ticks Up

NVR (NYSE: NVR) sits more in the middle of the market, with its average home selling price coming in at $457,000 in Q1 2026. This was squarely between Pulte’s $542,000 average selling price and D.R. Horton’s $362,000, showing the differences in income among their respective customers.

The company saw its revenues take a 21.7% hit, falling to $1.91 billion. This significantly missed the estimates of $2.09 billion. EPS fell by 28.6% to $67.76, missing estimates of $79.97 by a wide margin. The company’s gross margin compression mirrored D.R. Horton, with the figure falling 230 basis points to 19.6%.

However, like the other two names, new orders saw a moderate increase, rising by 7%. This was an improvement over the 4% increase in the prior quarter. NVR’s average selling price remained flat YOY, while the metric fell by 3% at Pulte and 5% at D.R. Horton. Combined with rising orders, this is a positive sign for NVR, showing that the company isn’t compromising on price to drive demand. Notably, NVR does not provide forward guidance. NVR shares fell 4.7% following the results.

Multiple analysts dropped their targets after the report, with updates averaging approximately $7,465, moderately below the consensus target near $7,650. This updated average target implies just under 15% upside in shares.

Homebuilders Continue to Face a Difficult Environment

Earnings across these three names showed a trend: revenue and margin hits across the industry. D.R. Horton was a bright spot, with the lowest sales decline and the highest order growth. Encouragingly, orders rose across all names, but the industry is still in a rut. Price targets remain relatively subdued, but point to upside ahead, indicating a degree of optimism among the analyst community.

Fixed rates on 30-year mortgages briefly fell below 6% prior to the conflict in the Middle East. Rates have since risen back to 6.2%. A clear end to the conflict would be a meaningful positive for homebuilders, likely helping rates approach 6% again, improving demand.

Ad Banyan Hill Publishing

The REAL Reason Trump is Invading Iran

The REAL Reason Trump is Invading IranClick Here To Find Out What It Is.

Unsubscribe

| Contact Us

MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.

RJ Hamster

The ‘missing scientists’ conspiracy theory, explained

Follow @FlipboardSee More in The Daily Edition Download App

What’s really underpinning the ‘missing scientists’ conspiracy theory Talking Points Memo · Mike Rothschild The “Curse of King Tut” is relevant.

The Trump administration is dismantling FOIA NOTUS · Shifra Dayak Long-standing backlog, staffing cuts and political pressure are threatening the Freedom of Information Act.

The city of Pittsburgh was the true star of the NFL Draft Sports Illustrated · Gilberto Manzano Steel City provided a memorable draft experience full of picturesque views and big crowds.

China surpasses U.S. in research spending theconversation.com · Caroline Wagner The consequences extend far beyond scientific ranking and clout.

Stay informed and inspired!

Download Flipboard to get the latest news and stories on the topics you care about.

Get the App

Ben Sasse’s solutions for a country consumed by ‘tribalism’ CBS News · Joe Walsh Late last year, the former U.S. senator was diagnosed with pancreatic cancer and given three to four months to live. Now, he’s on “extended time.”

Coffee may boost your mood and brainpower, even without caffeine ScienceAlert · Carly Cassella A new study has compared caffeinated and decaffeinated coffee and found that they both have potential perks for the gut, mood, and behavior.

The generation that got stuck in lockdown newrepublic.com · Jess Bergman The millennials in Andrew Martin’s new novel are treading water: caught between youth and age, breaking up, and settling down.

How they pulled it off: A Fla. beach house that’s survived three hurricanes dwell · Matt Shaw On the beaches of Sanibel Island, Fla., architects got to test their hurricane-proof design of a house in a very real way.

Unhealthiest fast food fries ranked worst to best cheapism.com · Alex Andonovska While none of them are exactly “health” food, some are far worse than others.

The strange comfort of a rewatch The Atlantic · Rafaela Jinich Even in the age of infinite options, people keep returning to the movies, shows, songs, and books they know by heart.

Was this sent to you by a friend? For more like it, subscribe here.BLOG · CAREERS · ADVERTISEUpdate your email preferences or unsubscribe here.View our privacy policy here.©2026 Flipboard, Inc. Made with love at 555 Bryant St #352 Palo Alto, CA 94301

RJ Hamster

Trump Recounts Shooting; The Left’s Radicalization; Suspect Manifesto

Breaking News from Newsmax.com

• Trump Says He ‘Wasn’t Worried’ During Dinner Shooting

Special: Final Days. AI Investors Are Moving. This Closes 4/30

• New York Post Pins Blame on ‘Radical Left’

• Trump: Suspect’s Manifesto Shows Anti-Christian Hate

SPONSOR

ADVERTORIAL

The Last Window Before Lock $0.91/share Now by April 30.

The last few days of a private round are where things move fast.

Allocations tighten. Late capital comes in. And access gets limited.

That’s where RAD Intel is right now.

This is a private AI company that has already raised $75M+ from over 20,000 investors, with backing from multiple Fidelity funds and selection by the Adobe Design Fund. It’s not early-stage theory. It’s a company already operating at scale inside a massive market.

RAD Intel operates inside a $1T+ digital advertising market where too many decisions still get made on instinct, lagging metrics, or static audience assumptions. Its technology helps brands and agencies understand how audiences think, respond, and engage before a campaign goes live, giving teams a stronger basis for creative, creator, and strategy decisions before money is committed.

That matters more as the ad market gets more competitive and more automated. A lot of AI in marketing still gets applied after launch, once spend is already in motion and the room for improvement is narrower.

RAD Intel is built further upstream, helping shape the decisions that drive campaign performance before creative is ever finalized. Its AI analyzes relevant online conversation in real time, giving brands a clearer read on how audiences are thinking, reacting, and engaging. That insight helps teams build ads that feel more connected to the conversation instead of cutting across it.

In fact, RAD’s AI platform has already delivered up to 3.5x ROI on Fortune 1000 campaigns, and continues to secure enterprise-level contracts across major brands.

That’s why this round has moved the way it has. Quickly. RAD Intel’s current Reg A+ offering is nearly full and on track to hit 85% this week.

The round closes April 30.

Shares remain available at $0.91 for just 3 more days through this SEC-qualified Reg A+ offering.

The AI market is no longer rewarding ideas alone. Capital is moving toward companies already proving they belong.

This is what early looks like. Do your diligence. The next phase won’t wait.

Invest now at $0.91/share.

This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company’s Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Brand references reflect factual platform use, not endorsement. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.

Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.

This email was sent by:
Newsmax.com
362 N. Haverhill Road
West Palm Beach, FL 33415 USA

DM951271
010502vdae4p

RJ Hamster

Presidential Security; UAE Pakistan Demand; Pope, Archbishop of Canterbury

Breaking News from Newsmax.com

• White House to Discuss Presidential Security, Stands by Secret Service

Special: Win a Holographic Weaponsight!

• UAE Seeks $3.5 Billion From Pakistan Over Iran War Role

• Pope, 1st Female Archbishop of Canterbury Meet

SPONSOR

ADVERTORIAL CLICK HERE TO LEARN HOW TO WIN!

GRAND PRIZE: EOTECH XPS2-0 W/ AMMO CAN FILLED W/ ARMSLIST SWAG

FOUR RUNNERS UP: AMMO CAN FILLED W/ ARMSLIST SWAG

Not an Armslist member? Click here to Join America’s #1 Firearms Marketplace for just $0.99 today with coupon code EOTECH26

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.

RJ Hamster

Calif. Billionaire Tax; Secret Service Failure; Court Sides With…

Breaking News from Newsmax.com

• California Billionaire Tax Likely Headed to Ballot

Special: Invest Before the Pre-IPO Round Closes – $0.72/Share.

• Rep. Perry: Attack on Trump an ‘Abject Failure’ of Secret Service

• Supreme Court Formally Reinstates Pro-Republican Texas Voting Map

SPONSOR

ADVERTORIAL

Over 1.5M People Replaced Their Monitors With This.

That’s not a marketing claim. It’s a usage metric.

Immersed built a spatial workspace, a virtual environment where professionals do their actual jobs. No prototype, no pilot program. Over 1.5M people use it as their primary workspace, and they’ve collectively logged the equivalent of more than 2,000 years of work time on the platform. Fortune 500 companies run daily operations inside it.

The business is real. The traction is real. The partnerships with Meta, Microsoft, Qualcomm, and Samsung are the result of a product that performs, not a pitch that promises.

Previous Intel CEO Pat Gelsinger invested personally. $28M+ raised from 7,000+ investors. NASDAQ ticker reserved: $IMRS. No. 1 productivity app in the Meta Quest Store.

They’re running a Regulation A+ offering, the same structure that allows retail investors to participate in a raise that would traditionally be limited to accredited investors. Pre-IPO shares are currently at $0.72. Early investors can qualify for up to 20% bonus shares. Minimum investment is $999. The round closes May 14th. The price won’t stay here.

Invest Before the Pre-IPO Round Closes →

Immersed is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular may be obtained here. The valuation is set by the Company and there is currently no public market for the Company’s Common Stock. NASDAQ ticker “IMRS” has been reserved by Immersed and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Forward-looking statements appear here based on current information and involve known and unknown risks, uncertainties, and other factors that may cause outcomes to differ. Please read the offering circular and related risks at invest.immersed.com.

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.

RJ Hamster

Dr. Oz: Vinegar Reduces Blood Pressure

Breaking News from Newsmax.com

Vinegar Helps Blood Pressure, Diabetes

By Dr. Mehmet Oz and Dr. Mike Roizen, MDs

Thirty-two thousand baby boomers are members of USA Triathlon, the national governing body for competitive triathletes; tens of thousands more cycle, swim, and jog regularly. An astounding 61 percent say they feel nine years younger than they really are.

All that get-up-and-go means the older generation has lots of energy, which of course translates into more active intimate relations.

In fact, today more than 70 percent of men and 50 percent of women in their 60s report that they’re still sexually active. A lot of kiss and vinegar, you might say!

That doesn’t surprise us, because it turns out that vinegar — whether apple cider, balsamic, or rice wine — is a smart part of a healthy lifestyle.

Special: Heart Surgeon’s Secret to Healthy Blood Pressure

Vinegar helps reduce blood pressure, improves your blood sugar response (reducing the effects of diabetes) and helps prevent heart disease. It has antibacterial properties and contains polyphenols and acetic acid.

The latter inhibits your body’s ability to store fat while boosting its ability to burn it! All that helps protect you against sexual dysfunction.

Just one word of caution: Good health and great romance call for smart protection against sexually transmitted diseases such as herpes, gonorrhea, and chlamydia. And baby boomers seem to be overlooking that!

The Centers for Disease Control and Prevention estimates that there are 20 million new sexually transmitted infections annually, but only half are among young people.

So what’s the solution? Stay energetic and engaged, for sure, but start relying on disease-protecting condoms for safety. With good-for-you condiments and condoms, you can go, go, go!

More Links:

Federal Authorities: You Need Emergency Radio

The Heart Surgeon’s Secret for Healthy Blood Pressure

Famed heart surgeon reveals what he recommends to patients who want to keep their blood pressure in the healthy zone.

By Nancy Reynolds
Reporting for Newsmax Health

Palm Beach Gardens, FL — “There’s a hidden reason why many people are still struggling with their blood pressure. And it may not be due to poor diet, lack of exercise, or too much salt.”

When a famed heart surgeon utters these words, it’s worth sitting up and taking notice.

That’s why we recently sat down with Dr. Chauncey Crandall to learn more about this missing link to healthy blood pressure. Dr. Crandall is chief of the Cardiac Transplant Program at the world-renowned Palm Beach Cardiovascular Clinic in Palm Beach Gardens, FL.

Dr. Crandall is also author of the No. 1 Amazon best-seller The Simple Heart Cure, and a frequent guest on national television and radio programs.

“As a medical doctor and natural health advocate, I credit my own robust health to a balanced approach, including a good diet, daily exercise, and targeted supplements,” Dr. Crandall said.

Why does Dr. Crandall feel so strongly about targeted supplements? I’ll tell you why in a moment. But first, let me tell you why you can no longer ignore this deadly health problem …

Silently Wreaking Havoc

If you’ve been told your blood pressure is higher than normal, then you are in serious danger.

Unhealthy blood pressure is called the “silent killer.” That’s because it quietly sneaks up on you … damaging your blood vessels without causing pain … until it’s too late.

Then disaster strikes in the form of a weakened heart, kidney problems, or perhaps circulation problems that can wreak havoc on your heart, brain, and eyes.¹

If left unchecked, unhealthy blood pressure, even in its mildest form, can lead to premature aging and serious brain damage.

What’s more, half of all people who have been diagnosed with unhealthy blood pressure still don’t have it under control.

On a Mission to Help People With Stubborn Blood Pressure Problems

“There are literally millions of Americans who are still struggling with their blood pressure,” Dr. Crandall said. “Many people are already trying diets, exercise, maybe even taking medications. Yet they are still not getting their blood pressure to where it should be.”

But there is a solution. “There are targeted nutrients that can help your body manage blood pressure naturally. But many people still don’t know about the extensive research behind them.

“That’s why I’ve made it my mission to get this information out to people,” Dr. Crandall said. He then revealed …

The Nobel Prize-Winning Discovery That Can Finally Give You Hope

In 1998, three scientists stepped to the podium in Stockholm, Sweden, and accepted the Nobel Prize for Medicine.²

They had discovered a special molecule in the human body called nitric oxide. It was soon dubbed the “miracle molecule” for its amazing effect on blood pressure and circulation.

Nitric oxide helps expand your blood vessels so more blood, oxygen, and nutrients can flow to every tiny capillary in your body. Doctors call this “vasodilation” but you’ll call it amazing. Hundreds of studies show nitric oxide helps:

Relax arteries so they expand easily, to promote optimal blood flow and healthy blood pressure.
Maintain soft, elastic blood vessels that support good cardiovascular health.
Support a strong immune system. Especially important during cold and flu season.
Promote peak performance in the bedroom. Nitric oxide plays a role in healthy erectile function.
Boost energy. Athletes use nitric oxide to get more oxygen flowing to their muscles. Weightlifters use it to get a serious boost!

When your circulation is working well … just about every part of your body works better!

But you can’t just go out and consume nitric oxide to get all these good things. Instead, your body produces a “precursor” — an amino acid called L-arginine — that kick-starts this process.

L-arginine is converted into nitric oxide, which helps dilate your blood vessels. This, in turn, means your heart doesn’t have to pump as hard, which promotes normal blood pressure and circulation.

Vanishing L-arginine

The trouble is, as you get older, your body produces less and less L-arginine. In fact, your L-arginine levels start to drop off as early as age 30. By the time you’re 50, chances are you’re not getting enough L-arginine to keep your arteries relaxed and flexible. And that’s not all …

The Big Problem With L-arginine

Ever since the discovery of nitric oxide and L-arginine, companies have rushed to market L-arginine supplements.

But if you’ve ever tried one, chances are you’ve been disappointed with the results. Why? Because your body absorbs and metabolizes L-arginine very quickly. So you’d have to take it all day long just to get results. That is, until now …

Now scientists have created a sustained release form of L-arginine that gives you a constant flow of L-arginine all day long. It releases artery-relaxing L-arginine continually for 24 hours.

In fact, when researchers tested this new form of L-arginine … it lived up to its promise. They noticed significant support for cardiovascular health in nearly seven out of 10 patients. And they noticed the difference in as little as seven days.³

So if you want to maintain normal blood pressure and get all the benefits of L-arginine … sustained-release L-arginine should be at the top of your list.

That’s why Dr. Crandall recently teamed up with experts at Medix Select to create an advanced blood pressure formula with 3 grams of sustained-release L-arginine called Ventricore™.

But he didn’t stop there … because there are other nutrients that support healthy blood pressure and circulation. They include:

I’ll tell you more about these nutrients in a moment. But first … Dr. Crandall believes so strongly in Ventricore that he has asked Medix Select to reserve a trial supply just for you to try — at no risk.

This way you can try Ventricore for yourself — and see the effect it has on your blood pressure and healthy circulation.

That is almost a $40 value that you can get for just $4.95 to help cover shipping and handling. If you like Ventricore, simply do nothing and you will receive it at over 33% off the regular price through our convenient Smart Ship Program — only $26.63 a bottle.

Tell us where to send your bottle of Ventricore and we’ll rush it out to you!

No worries, either. You can cancel at any time and your satisfaction is guaranteed.

Claim Your Trial Bottle of Ventricore Today — Just Pay $4.95 Shipping!
Or Call Toll-Free (877) 214-0716

About Dr. Chauncey Crandall

Dr. Chauncey W. Crandall, M.D., F.A.C.C., is chief of the Cardiac Transplant Program at the world-renowned Palm Beach Cardiovascular Clinic in Palm Beach Gardens, Fla., where he practices interventional, vascular, and transplant cardiology. He is the author of the Amazon best-seller The Simple Heart Cure, and makes frequent guest appearances as a heart expert on national television and radio programs. He also lectures regularly, both nationally and internationally, about preventive cardiology, cardiology healthcare of the elderly, healing, interventional cardiology, and heart transplants. Dr. Crandall received his post-graduate training at Yale University School of Medicine, where he also completed three years of research in the Cardiovascular Surgery Division.

What About the 5 Other Ingredients in Ventricore?

Time-released L-arginine is a good start for healthy blood pressure. But when you combine it with a few other circulation-boosting nutrients …

. . . that’s when you REALLY have a chance to ”move the needle” at your next check-up! That’s why Dr. Crandall decided to include these five other ingredients in Ventricore™.

Alpha Lipoic Acid (ALA) — For Combating Free Radicals

Your body is under constant assault from pollution, toxins, harmful chemicals in food, and even waste products from normal metabolism. All these can lead to a build-up of nasty free radicals that can damage your cells.

That’s why you need to neutralize free radicals as fast as possible. One of the best ways is with an antioxidant called alpha lipoic acid or ALA.

ALA helps neutralize free radicals. It also helps your body recycle more of your master antioxidant, glutathione.⁵ And by the way … glutathione plays a role in your body’s ability to use nitric oxide for optimal blood flow.⁶

Folic Acid — To Keep Your Homocysteine Levels in Check

You’ve probably heard of homocysteine. It’s one of the things your doctor checks on your regular blood tests. Homocysteine is a marker for inflammation that is associated with impaired heart health.

Researchers have found that a B vitamin — folic acid — supports a better balance of homocysteine in your body. And folic acid works especially well when it’s combined with another B vitamin …

Vitamin B12 — To Get More Oxygen-Rich Blood to Every Cell in Your Body

Like folic acid, vitamin B-12 also helps balance your levels of homocysteine.

B12 is vital for healthy red blood cells as well. Increasing your red blood cells can boost the amount of oxygen that gets to your heart and muscles for more energy.

B12 also enhances the ability of your cells to use nitric oxide generated by L-arginine.⁷ And it protects the delicate lining around your nerves, which plays a role in regulating your blood pressure.

But as we get older, we have a harder time absorbing B12 from our food. In fact, nearly two out of five Americans might not be getting enough B12.⁸

Vitamin C — To Support Your Ability to Release Nitric Oxide

Like ALA, vitamin C is a powerful antioxidant that fights free radicals. It also helps support your blood vessels’ ability to release nitric oxide, to promote blood flow and support healthy blood pressure.

A study of young adult women found that those with the highest levels of vitamin C tended to have healthier blood pressure levels.

In fact, a review of 29 different studies and 1,400 patients by researchers at Johns Hopkins University shows that vitamin C can have a clear effect on supporting healthy blood pressure.

Vitamin D — The Overlooked Vitamin for a Healthy Heart

Scientists now realize that vitamin D — yes, the sunshine vitamin! — plays a much bigger role in maintaining heart health than previously thought.

For example, a study by Emory University looked at people with low levels of vitamin D. Researchers found that the lower your vitamin D, the less your blood vessels are able to relax.

Vitamin D also plays a role in bone health, immune function, inflammatory response, and energy.

Despite all this, most Americans still don’t get anywhere near the amount of vitamin D they should.⁹ That’s true even down in sunny Florida, where many of Dr. Crandall’s patients live.

‘The Targeted Blood Pressure Supplement I Trust More Than Any Other’

Dr. Crandall looked at many alternatives when it came to blood pressure supplements. He has yet to find one that matches the strategic blend of L-arginine, folic acid, alpha lipoic acid (ALA), vitamin B12, vitamin C, and vitamin D found in Ventricore.

He wanted to create a formula that covers all the bases when it comes to keeping your arteries healthy and supporting healthy circulation. And he wanted to make it affordable, too.

That’s why he recommends Ventricore to everyone who wants to help maintain normal blood pressure — and that includes just about everyone over 40.

Order Your Risk-Free Trial Bottle and Start Feeling Better Sooner

So what’s stopping you? Especially when you can try Ventricore for nothing more than a small shipping charge?

You deserve the peace of mind that you are doing something smart and positive for your blood pressure and your heart.

That’s why I want to make sure you get a bottle to try for yourself. And please remember …

Even a Small Change inYour Blood Pressure CanMake a BIG Difference!

Studies show that even a small improvement in your blood pressure can significantly reduce your risk of a serious heart or brain disaster.¹⁰ So why not take this small step today? You have so much to gain.

Imagine not having to worry about your blood pressure and circulation any longer …

Imagine feeling energized and alert again … able to tackle anything you want. Whether it’s taking long walks, shopping, playing golf or tennis, dancing … or just being able to chase the grandkids around the house. Without feeling worn-out and tired.

You’re going to love the feeling of energy and vitality you get from Ventricore.

Ask for Your Bottle of Ventricore Today! Or Call Toll-Free (877) 214-0716

Scientific References
(01) heart.org
(02) nobelprize.org
(03) ncbi.nlm.nih.gov/pubmed/16597191
(04) ncbi.nlm.nih.gov/pmc/articles/PMC3249911/
(05) ncbi.nlm.nih.gov/pubmed/18315507
(06) content.onlinejacc.org/article.aspx?articleid=1125915
(07) ncbi.nlm.nih.gov/pubmed/15632180
(08) ars.usda.gov/is/pr/2000/000802.htm
(09) medicaldaily.com/most-americans-dont-get-enough-nutrients-they-consume-over-top-levels-fat-and-sodium-study-308141
(10) nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.